x

Ncardia and Evotec Entered a Licencing Agreement for Disease Modelling Using iPS Cells

01 December, 2017

GOSSELIES, Belgium--()--Ncardia, a leader in standardised, validated iPSC assays for safety, phenotypic screening and disease modeling, announced today that they entered into a global non-exclusive IP licensing agreement with Evotec (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809).

Click here to read the full article on BusinessWire